undamentalytics Newsletter
Sign in

Bionano Genomics, Inc. revenue

Bionano Genomics, Inc.'s revenue was $28.5m in fiscal 2025, down 7.4% on the year before. Since fiscal 2017 ($9.5m) it has grown at a compound 14.7% a year. Over the last twelve months it was $30.2m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1012109182836312930
Growth on the year before—+26.3%−15.6%−16.1%+111.5%+54.6%+29.9%−14.8%−7.4%—
Gross profit3333461001314
Gross margin36.6%27.4%33.2%32.6%21.5%21.4%26.5%1.2%46.3%47.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $26.7M 93.8% ▼ 1.0%
Consumable Revenue $14M 52.2% ▲ 9.4%
Software Revenue $6.4M 24.0% ▲ 3.5%
Instrument Revenue $6.4M 23.8% ▼ 20.9%
Other $1.8M 6.2% ▼ 53.2%
Geography
Region Revenue Share YoY
EMEA $14.1M 49.5% ▼ 0.9%
Americas $12.2M 42.7% ▼ 10.8%
Asia Pacific $2.2M 7.8% ▼ 23.3%

From Bionano Genomics, Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bionano Genomics, Inc. $30.2m 10.0% -1.4%
Maxcyte, Inc. $31.1m -13.2% -8.6%
Rapid Micro Biosystems, Inc. $35.2m 16.1% 22.5%
Omniab, Inc. $40.2m 90.6% -14.7%
Alpha Teknova, Inc. $43.7m 12.3% 3.7%
Champions Oncology, Inc. $60.7m 6.7% 4.8%

Compare with peers

Head to head: BNGO vs MXCTBNGO vs RPIDBNGO vs OABI

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bionano Genomics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bionano Genomics, Inc.